ET-traps
ET-traps
  • ET-traps
  • ABOUT
  • TECHNOLOGY
  • ADVANTAGES
  • CLINICAL APPLICATIONS
  • INVESTORS
  • TEAM
  • NEWS
  • CONTACT
  • SCIENTIFIC PUBLICATIONS
    • ET-traps
    • ABOUT
    • TECHNOLOGY
    • ADVANTAGES
    • CLINICAL APPLICATIONS
    • INVESTORS
    • TEAM
    • NEWS
    • CONTACT
    • SCIENTIFIC PUBLICATIONS
  • ET-traps
  • ABOUT
  • TECHNOLOGY
  • ADVANTAGES
  • CLINICAL APPLICATIONS
  • INVESTORS
  • TEAM
  • NEWS
  • CONTACT
  • SCIENTIFIC PUBLICATIONS

SCIENTIFIC PUBLICATIONS

image478

COVID-19

Latest publication on the potential use of ET-traps for COVID-19. It should be noted that we have already established proof-of-concept both at the in vitro and in vivo levels in the diabetes disease space. And diabetics are at higher risk of a serious COVID-19 infection. This paper also fully discusses the merits of ET-traps as a potential therapeutic for the COVID-19 pandemic. 


This article has been published in the Medicine in Drug Discovery, June 2020 Read more

image479

Autoimmune diseases

New academic paper has been published in "Drug Discovery Today" entitled "ET-traps offer a potential therapeutic tool for use in different autoimmune diseases", April 2020  Read more.

image480

Neurological disorders

Dr Arjun Jain's Review article - "ET-traps-a Novel Therapeutic for Treatment of Neurological Disorders" , 6 November, 2019. Read more

image481

ET-traps: from diabetes to beyond

New academic paper has been published in "Drug Discovery Today" entitled "Endothelin-1 traps as a potential therapeutic tool: from diabetes to beyond?", September 2019. Read more

image482

Animal studies on the efficacy of ET-traps for type-1 diabetes

New academic paper has been published in the "Journal of Diabetes & Metabolic Disorders " entitled " In vivo studies demonstrate that endothelin-1 traps are a potential therapy for type I diabetes".

Read More →Mar14, 2019

image483

In vitro studies on the efficacy of ET-traps for diabetes

Another publication pertaining to ET-traps was published in the "Journal of Diabetes & Metabolic Disorders " entitled "Endothelin-1 traps potently reduce pathologic markers back to basal levels in an in vitro model of diabetes".

Read More →Oct1, 2018

Copyright © 2021  ET-traps  Limited- All Rights Reserved.

  • ABOUT
  • TECHNOLOGY
  • ADVANTAGES
  • CLINICAL APPLICATIONS
  • INVESTORS
  • TEAM
  • NEWS
  • CONTACT
  • SCIENTIFIC PUBLICATIONS